Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Sha, Sue ^a   Devineni, Damayanthi ^a   Ghosh, Atalanta ^a   Polidori, David ^b   Hompesch, Marcus ^c   Arnolds, Sabine ^c   Morrow, Linda ^c   Spitzer, Heike ^c   Demarest, Keith ^a   Rothenberg, Paul ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Profil Institut für Stoffwechselforschung GmbH ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BUTOCONAZOLE; CANAGLIFLOZIN; EXENDIN 4; GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLUCOSIDE; THIOPHENE DERIVATIVE;

ADULT; AGED; APPLICATION SITE IRRITATION; ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ELECTROLYTE URINE LEVEL; ERYTHEMA; EVENING DOSAGE; FEMALE; GERMANY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; KIDNEY FUNCTION; KOREA; LABORATORY TEST; LICHENOID ERUPTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; TREATMENT DURATION; UNITED STATES; URINE VOLUME; VAGINA CANDIDIASIS; VITAL SIGN; WEIGHT REDUCTION; BLOOD; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY; MALE; MIDDLE AGED; THIOPHENES;

EID: 84919649970     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105638     Document Type: Article

References (32)

1. Wright EM, Hirayama BA, Loo DF (2007) Active sugar transport in health and disease. J Intern Med 261: 32-43. (Pubitemid 46046470)
2. Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27: 136-142.
3. Wright EM (2001) Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 280: F10-F18.
4. Abdul-Ghani MA, Norton L, Defronzo RA (2011) Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 32: 515-531.
5. Bays H (2009) From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 25: 671-681.
6. Chao EC, Henry RR (2010) SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov 9: 551-559.
7. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K (2013) Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 41: 72-84.
8. Cefalu WT, Leiter LA, Yoon K-H, Arias P, Niskanen L, et al. (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382: 941-950.
9. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, et al. (2012) Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35: 1232-1238.
10. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, et al. (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 36: 2508-2515.
11. Stenlöf K, Cefalu WT, Kim K-A, Alba M, Usiskin K, et al. (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15: 372-382.
12. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, et al. (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15: 463-473.
13. Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, et al. (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56: 2582-2592.
14. INVOKANA (2013) (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals.
15. Wilding JP, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, et al. (2013) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 67: 1267-1282.
16. Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, et al. (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 16: 467-477.
17. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, et al. (2012) Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 14: 539-545.
18. Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, et al. (2013) Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 98: E867-E871.
19. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, et al. (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13: 669-672.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470. (Pubitemid 29135798)
21. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, et al. (2013) Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 53: 601-610.
22. Magni L, Raimondo DM, Bossi L, Man CD, De Nicolao G, et al. (2007) Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol 1: 804-812.
23. Ganong WF (2005) Formation and excretion of urine. Renal function and micturition. In: Foltin J, Lebowitz H, Brown RY, editors. Review of Medical Physiology. 22 ed. New York, NY: Lange Medical Books/McGraw-Hill. 699-728.
24. Rave K, Nosek L, Posner J, Heise T, Roggen K, et al. (2006) Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant 21: 2166-2171. (Pubitemid 44295041)
25. Mogensen CE (1971) Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 28: 101-109.
26. Farber SJ, Berger EY, Earle DP (1951) Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30: 125-129.
27. Defronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, et al. (2013) Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36: 3169-3176.
28. Freitas HS, Anhe GF, Melo KF, Okamoto MM, Oliveira-Souza M, et al. (2008) Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 149: 717-724. (Pubitemid 351159342)
29. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, et al. (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427-3434. (Pubitemid 43334332)
30. Vestri S, Okamoto MM, de Freitas HS, parecida Dos SR, Nunes MT, et al. (2001) Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 182: 105-112. (Pubitemid 32641748)
31. Defronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773-795.
32. Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, et al. (2014) Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 30: 1109-1119.